Gogoro Inc vs Kymera Therapeutics Inc. Common Stock — how do they compare? Gogoro Inc trades at $2.75 (market cap $65.04M), while Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 136.4× Gogoro Inc's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Gogoro Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gogoro Inc for 14 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| GGR | KYMR | |
|---|---|---|
Market Cap | $65.04M | $8.87B |
Volume | 21,493 | 779,107 |
Sector | Consumer Cyclical | Health |
52-Week High | $4.66 | $127.31 |
52-Week Low | $2.20 | $55.80 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $351.48M | $8.26B |
Signals from Pluang's Aura AI — not financial advice
GGR trades at $3.24, up 2.53% with a bullish technical signal despite negative profitability metrics. The company reported $281.48M revenue for 2025 but a net loss of $79.97M, though losses are projected to narrow in 2026. Recent developments include $61.8M in new equity investments and board appointments to strengthen governance. Technical indicators show bullish momentum with support at $3.00.
While technical momentum appears positive, fundamental challenges persist with negative margins and cash flow. The investment case hinges on Gogoro's ability to achieve profitability amid expansion costs. Analyst consensus remains cautious with 100% hold ratings, suggesting investors await clearer profitability signals before committing.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →